Pharmacoeconomic analysis of the etravirine compared to raltegravir in treatment HIV-infected adult patients, previously treated with antiretroviral drugs
Abstract
Objective: To perform comprehensive pharmacoeconomical assessment of use etravirine and raltegravir in HIV-infected patients. Methodology: Cost-eifectiveness and budget impact analyses of etravirine or raltegravir on the top of optimized background therapy in adult treatment-experienced HIV-infected patients were conducted. Results: Cost to achieve an undetectable viral load (<50 copies/ml) were 2 958 646 rubles for etravirine-based treatment regimen and 3 859 041 rubles for raltegravir-based therapy per one HIV-infected patient treated within two years. Use of etravirine instead of raltegravir associated with budget savings in the amount of 513 225 rubles per one HIV-infected patient treated during two years. Conclusions: Etravirine shown to outperform raltegravir in terms of cost-effectiveness and budget savings in management of adult treatment-experienced HIV-infected patients.
About the Authors
Y. I. Ashikhmin
LLC "Center for Pharmacoeconomics Research", Moscow
Russian Federation
Russian Federation
D. Yu. Belousov
LLC "Center for Pharmacoeconomics Research", Moscow
Russian Federation
Russian Federation
References
1. Cahn R, et al. Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority (SAILING study). // Lancet 2013; 382: 700-08.
2. Elion R. A Randomized Phase 3 Study Comparing Once-Daily Elvitegravir With Twice-Daily Raltegravir in Treatment-Experienced Subjects With HIV-1 infection: 96-Week Results. // J Acquir Immune Defic Syndr 2013;63:494-497.
3. Eron J. etal. Clinical endpoints reduced through etravirine use in treatment-experienced, HIV-1-infected patients: pooled 96-week results from the Phase III DUET trials. Presented at the 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention, Cape Town, South Africa, 19-22 July 2009.
4. Eron J. et al. Efficacy and safety of raltegravir for treatment of HIV for 5 years in the BENCHMRK studies: final results of two randomised, placebo-controlled trials. // Lancet Infect Dis 2013; 13: 587-96.
5. Jamison D. T., Jamison J.S. Discounting. 4. 2003. Bethesda, Fogarty International Center, National Institute of Health. Disease Control Priority Project Working Paper.
6. Katlama C. et al. Short communication Efficacy and safety of etravirine at week 96 in treatment-experienced HIV type-l-infected patients in the DUET-1 and DUET-2 trials. // Antiviral Therapy 2010, vol. 15, no. 7, pp. 1045-1052.
7. L6pez-Cort6s L., et al. Clinical and Virological Efficacy of Etravirine Plus Two Active Nucleos(t)ide Analogs in an Heterogeneous HIV-Infected Population. // PLOS one (2014): Є97262.
8. Martinez E., et al. Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study. // Aids 24.11 (2010): 1697-1707.
9. Nguyen A., etal. A randomized cross-over study to compare raltegravir and efavirenz (SWITCH-ER study). // Aids 25.12 (2011): 1481-1487.
10. Steigbigel R. et al. Long-Term Efficacy and Safety of Raltegravir Combined with Optimized Background Therapy in Treatment Experienced Patients with Drug Resistant HIV Infection: Week 96 Results of the BENCHMRK 1 and 2 Phase III Trials. // Clinical Infectious Diseases 2010; 50:605-12.
11. Steigbigel R. etal. Raltegravir with Optimized Background Therapy for Resistant HIV-1 Infection. // N Engl J Med 2008; 359:339-354.
12. Генеральное тарифное соглашение ФОМС Санкт-Петербурга, 2015 год. http://www.spboms.ru/kiop/main?page_id=338 (по состоянию на 24.05.2015).
13. Государственный реестр лекарственных средств, по состоянию на 24.05.2015 г. http://grls.rosminzdrav.ru/Default.aspx.
14. Интернет-сайт независимой лаборатории «Инвитро», по состоянию на 24.05.2015 г. http://invitro.ru.
15. Мазус А.И., Каминский Г.Д., Зимина В.Н. и соает. Национальные клинические рекомендации по диагностике и лечению ВИЧ-инфекции у взрослых. М., 2013, 68 стр.
16. Отраслевой стандарт «Клинико-экономические исследования. Общие положения» Приказ Минздрава РФ от 27.05.2002 №163 вместе с ост 91500.14.0001-2002 [Электронный ресурс]. http://www.healtheconomics.ru/index.php?option=com_content&view=article8dd=300:-q-q&catid=55:2009- 05-29-19-56-44&Itemid= 104.
17. Рекомендации EACS, версия 7.01, ноябрь 2013 г.
18. Сайт Федерального научно-методологического центра по профилактике и борьбе со СПИДом. http://www.hivrussia.org/files/spravkaHIV2014.pdf.
Review
For citations:
Ashikhmin Y.I., Belousov D.Yu. Pharmacoeconomic analysis of the etravirine compared to raltegravir in treatment HIV-infected adult patients, previously treated with antiretroviral drugs. Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice. 2015;(3):60-71. (In Russ.)
Views:
1364
Email this article 